Future collaborations to build Shire PLC 's ophthalmology activities could in theory resemble that signed this week with US-based biotech Parion Sciences Inc., whereby the Dublin-based, London-listed group acquired worldwide rights to a Phase II dry eye disease drug dubbed P-321.
With Parion Deal Done, Shire CEO Looks To Next Bright Ophthalmic Innovation
Shire's CEO Flemming Ornskov says he's focused on the specialist pharma's emerging ophthalmics division - and open to fresh innovative collaborations like that signed this week with Parion Sciences.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.